University of Medicine and Pharmacy, Pulmonary Disease University Hospital, Division of Pulmonary Disease, Iasi 700115, Romania.
Expert Opin Biol Ther. 2013 Feb;13(2):257-68. doi: 10.1517/14712598.2012.758247. Epub 2013 Jan 3.
In asthma and chronic obstructive pulmonary disease (COPD), the inflammation in the airways cannot always be controlled with conventional therapies, such as inhaled corticosteroids. Addition of more specific anti-inflammatory therapies, such as monoclonal antibodies, against inflammation pathways might improve the disease outcome.
This review individually discusses the major inflammation pathways and their potential blocking monoclonal antibodies in asthma and COPD.
The current use of omalizumab in asthma provides a good example on the potential therapeutic role of monoclonal antibodies in both asthma and COPD. There are many other monoclonal antibodies which are currently investigated as possible therapies in these diseases. The identification of the disease subsets in which such antibodies might exert the maximum benefit opens the door for personalized medicine and for targeted biological therapy in asthma and COPD.
在哮喘和慢性阻塞性肺疾病（COPD）中，气道炎症不能总是通过常规治疗（如吸入皮质类固醇）得到控制。添加更特异的抗炎治疗，如针对炎症途径的单克隆抗体，可能会改善疾病结局。
本文单独讨论了哮喘和 COPD 中主要的炎症途径及其潜在的阻断性单克隆抗体。
目前奥马珠单抗在哮喘中的应用为单克隆抗体在哮喘和 COPD 中的潜在治疗作用提供了一个很好的范例。目前还有许多其他单克隆抗体被作为这些疾病的潜在治疗方法进行研究。鉴定这些抗体可能发挥最大益处的疾病亚群为哮喘和 COPD 的个体化医学和靶向生物治疗开辟了道路。
